Odyssey Health (OTC: ODYY) announced in August the completion and findings of cohort I of the multiday ascending dosing (“MAD”) stage of its ongoing phase I clinical trial showing that PRV-002 was safe and well tolerated. A recent article reads: “Additionally, pharmacokinetic (‘PK’) analysis of the data from the first cohort provided new information that supports the hypothesis that more drug is getting to the brain itself than the circulation… The PK analysis further showed that the blood levels of the intranasally administered active drug were substantially lower on average than what would ordinarily be expected with other routes of administration. ‘The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects,’ commented Dr. Dallas Hack, MD, a member of the Safety Review Committee… On his part, Odyssey’s Head of Drug Development, Dr. Jacob VanLandingham, believes intranasal brain-targeting will be instrumental in the success of PRV-002 should it be efficacious for concussed patients in the planned phase II/III trials.”
To view the full article, visit https://ibn.fm/qOwdm
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: : The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php